CytomX Therapeutics, Inc. (NASDAQ:CTMX), a clinical-stage biotechnology company developing masked, conditionally activated biologics (PROBODY® therapeutics) for cancer, announced its fourth quarter and full-year 2025 financial results on March 16, 2026, before market open, with a conference call at 8:00 a.m. ET (BMO).
For the quarter ended December 31, 2025, the company reported a quarterly adjusted loss of $0.22 per share (vs. Zacks estimate of -$0.08 loss) and revenue of $0.66 million (sharply down from $38.09 million in the year-ago quarter, primarily due to completion of major collaboration obligations, e.g., with Bristol Myers Squibb, and slower recognition from partners like Moderna, Astellas, and Regeneron).
Full-year 2025 revenue was $76.2 million (down ~44.8% from 2024's $138.1 million), with the company ending the year with $137.1 million in cash, cash equivalents, and investments, providing a runway into the second quarter of 2027. The company highlighted progress in its pipeline, including Varsetatug Masetecan (EpCAM PROBODY® ADC) and CX-801, with ongoing clinical data expected.
Despite the revenue headwinds from maturing collaborations, CytomX maintains a solid cash position and continues advancing its innovative conditionally activated therapies. Stock reacted positively post-release. For the latest details, refer to the company's IR site or filings.
